Longeveron (LGVN) Interest Coverage Ratio Growth (3y) (2023 - 2026)
Longeveron (LGVN) Interest Coverage Ratio Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -42.41% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | 28.11% |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | -6.89% |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | 79.27% |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 40.09% |
| 10 | Longeveron | 15.29 Bn | 15.27 Bn | 264,000.00 | -268.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -268.32% |
| Dec 31, 2025 | -26.30% |
| Sep 30, 2025 | 40.09% |
| Jun 30, 2025 | 14.02% |
| Mar 31, 2025 | 6.59% |
| Dec 31, 2024 | -282.22% |
| Sep 30, 2024 | -323.89% |
| Jun 30, 2024 | -504.29% |
| Mar 31, 2024 | -338.79% |
| Dec 31, 2023 | 27.53% |
| Sep 30, 2023 | 32.13% |
| Jun 30, 2023 | 41.94% |
| Mar 31, 2023 | 81.42% |